Matthews Joseph J, Creighton Jade V, Donaldson James, Swinton Paul A, Kyrou Ioannis, Bellary Srikanth, Idris Iskandar, Santos Lívia, Turner Mark D, Doig Craig L, Elliott-Sale Kirsty J, Sale Craig
Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging & Longevity, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Sport, Health and Performance Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
Obesity (Silver Spring). 2025 Feb;33(2):278-288. doi: 10.1002/oby.24204. Epub 2025 Jan 12.
Overweight and obesity are characterized by excess adiposity and systemic, chronic, low-grade inflammation, which is associated with several metabolic disorders. The aim of this study was to assess the feasibility and tolerability of β-alanine supplementation and to explore the effects on cardiometabolic health and cardiovascular, hepatic, and renal function in adults with overweight and obesity.
A total of 27 adults (44% female; mean [SD], age: 58 [10] years, BMI: 31.1 [2.9] kg/m, hemoglobin A1c: 39.8 [4.3] mmol/mol) received β-alanine (4.8 g/day) or a matched placebo for 3 months. Feasibility and tolerability outcomes included adherence, side effects, recruitment, attrition, and blinding, and exploratory outcomes included biochemical markers, blood pressures, and transthoracic echocardiography parameters. Data were analyzed using a Bayesian approach presented with 95% credible intervals (CrI).
β-alanine was well tolerated and adhered to (adherence: placebo, 0.91 [95% CrI: 0.84-0.95]; β-alanine, 0.92 [95% CrI: 0.85-0.95]), and side effects remained at or below baseline throughout. The probability that β-alanine supplementation affected cardiometabolic, cardiovascular, or clinical biochemical outcomes was low.
Sustained-release β-alanine supplementation is well tolerated and adhered to in adults with overweight and obesity. Future research should consider more advanced metabolic conditions, which may benefit from longer duration supplementation.
超重和肥胖的特征是脂肪过多以及全身性、慢性、低度炎症，这与多种代谢紊乱相关。本研究的目的是评估补充β-丙氨酸的可行性和耐受性，并探讨其对超重和肥胖成年人心脏代谢健康以及心血管、肝脏和肾脏功能的影响。
共有27名成年人（44%为女性；平均[标准差]年龄：58 [10]岁，体重指数：31.1 [2.9] kg/m²，糖化血红蛋白：39.8 [4.3] mmol/mol）接受β-丙氨酸（4.8克/天）或匹配的安慰剂，为期3个月。可行性和耐受性结果包括依从性、副作用、招募、损耗和盲法，探索性结果包括生化指标、血压和经胸超声心动图参数。使用呈现95%可信区间（CrI）的贝叶斯方法分析数据。
β-丙氨酸耐受性良好且依从性高（依从性：安慰剂组为0.91 [95% CrI：0.84 - 0.95]；β-丙氨酸组为0.92 [95% CrI：0.85 - 0.95]），且副作用在整个过程中保持在基线水平或以下。补充β-丙氨酸影响心脏代谢、心血管或临床生化结果的可能性较低。
超重和肥胖成年人对缓释β-丙氨酸补充剂耐受性良好且依从性高。未来的研究应考虑更晚期的代谢状况，其可能从更长时间的补充中获益。
